Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 15/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9493953 | 0.83 | CHRNA7 (0.50) | CHRNA7OPRM1OPRK1 | |
| SCHEMBL9496731 | 0.83 | CHRNA7 (0.50) | CHRNA7OPRM1OPRK1 | |
| SCHEMBL7620120 | 0.81 | SLC18A3 (0.45) | CHRNA7TSHROPRM1OPRK1 | |
| SCHEMBL7623805 | 0.81 | SLC18A3 (0.45) | CHRNA7TSHROPRM1OPRK1 | |
| SCHEMBL7620113 | 0.81 | SLC18A3 (0.45) | CHRNA7TSHROPRM1OPRK1 | |
| SCHEMBL7623817 | 0.81 | SLC18A3 (0.45) | CHRNA7TSHROPRM1OPRK1 | |
| SCHEMBL7620129 | 0.81 | SLC18A3 (0.45) | CHRNA7TSHROPRM1OPRK1 | |
| SCHEMBL13457953 | 0.79 | SLC9A3 (0.49) | SLC9A3CHRNA7CYP2D6TSHROPRM1 | |
| SCHEMBL12362862 | 0.79 | HTR1A (0.54) | SLC9A3CHRNA7TSHR | |
| SCHEMBL8165906 | 0.79 | HTR1A (0.54) | SLC9A3CHRNA7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2022165402-A1 | INHIBITORS OF PROTEIN KINASE A | BLUEPRINT MEDICINES CORPORATION (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | SLC9A3 1765/4885CHRNA7 1658/4885CYP2D6 1500/4885 |
| US-20240132490-A1 | INHIBITORS OF PROTEIN KINASE A | PRKCA, MAP3K6, MAP3K1 | SLC9A3 3897/4885CHRNA7 4412/4885CYP2D6 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.